<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01339481</url>
  </required_header>
  <id_info>
    <org_study_id>2408-CL-0103</org_study_id>
    <nct_id>NCT01339481</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Receptor Occupancy of CD86 and CD80 in Subjects With Rheumatoid Arthritis Initiating Abatacept</brief_title>
  <official_title>A Phase 0, Open-Label, Multi-Center, Observational Study to Assess the Receptor Occupancy of CD86 and CD80 in Subjects With Rheumatoid Arthritis Initiating Abatacept</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Perseid Therapeutics LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to characterize CD86 receptor occupancy in subjects with
      rheumatoid arthritis (RA) receiving abatacept.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>CD86 Receptor Occupancy</measure>
    <time_frame>Day 1, Weeks 2, 4, 8, and 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>CD80 Receptor Occupancy</measure>
    <time_frame>Day 1, Weeks 2, 4, 8, and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abatacept serum concentration</measure>
    <time_frame>Day 1, Weeks 2, 4, 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Day 1 to Week 12 in Subject's Global Assessment of Arthritis</measure>
    <time_frame>Day 1 and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Day 1 to Week 12 in Physician's Global Assessment of Arthritis</measure>
    <time_frame>Day 1 and Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by adverse event reporting including Physical Examination findings</measure>
    <time_frame>Day 1 through Week 12 post-infusion</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">26</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Subjects with RA initiating abatacept treatment regimen</arm_group_label>
    <description>Subjects naïve to both abatacept and belatacept</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>abatacept</intervention_name>
    <description>Intravenous Infusion</description>
    <arm_group_label>Subjects with RA initiating abatacept treatment regimen</arm_group_label>
    <other_name>Orencia</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood, serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with Rheumatoid Arthritis
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has rheumatoid arthritis (RA), is both abatacept- and belatacept-naïve, and is
             an eligible candidate to start a course of treatment with abatacept in accordance with
             the product label

          -  Subject is willing and able to comply with study visits and procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Global Development</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Principal Investigator</last_name>
    <role>Principal Investigator</role>
    <affiliation>Metroplex Clinical Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pinnacle Research Group, LLC</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Research of Florida</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <zip>34684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Rheumatology and Bone Research</name>
      <address>
        <city>Wheaton</city>
        <state>Maryland</state>
        <zip>20902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore - Long Island Jewish Health System</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altoona Center for Clinical Research</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Low County Rheumatology</name>
      <address>
        <city>North Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metroplex Clinical Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2011</study_first_submitted>
  <study_first_submitted_qc>April 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2011</study_first_posted>
  <last_update_submitted>November 28, 2011</last_update_submitted>
  <last_update_submitted_qc>November 28, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 29, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Orencia</keyword>
  <keyword>Abatacept</keyword>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>Infusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abatacept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

